A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

June 15, 2026

Study Completion Date

June 15, 2026

Conditions

Prostate CancerRadical Prostatectomy

Interventions

DRUG

REGN5678

Given by IV (vein)

DRUG

Piflufolastat F18

Given by IV (vein)

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER